No improvement of survival with reduced- versus high-intensity conditioning for allogeneic stem cell transplants in Ewing tumor patients

Epigenetic maintenance of stemness and malignancy in peripheral neuroectodermal tumors by EZH2

(2011) Stefan Burdach et al.   CELL CYCLE

Regression modeling of competing risk using R: an in depth guide for clinicians

(2010) L Scrucca et al.   BONE MARROW TRANSPLANTATION

Total body MRI-governed involved compartment irradiation combined with high-dose chemotherapy and stem cell rescue improves long-term survival in Ewing tumor patients with multiple primary bone metastases

(2009) S Burdach et al.   BONE MARROW TRANSPLANTATION

The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES)

(2009) Julia Haeusler et al.   CANCER

Allogeneic Stem Cell Transplantation Is Able to Induce Long-Term Remissions in Angioimmunoblastic T-Cell Lymphoma: A Retrospective Study From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

(2009) Charalampia Kyriakou et al.   JOURNAL OF CLINICAL ONCOLOGY

EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation

(2009) G. H. S. Richter et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Graft-versus-leukemia effects of transplantation and donor lymphocytes

(2008) H.-J. Kolb   BLOOD

Results of the EICESS-92 Study: Two Randomized Trials of Ewing's Sarcoma Treatment—Cyclophosphamide Compared With Ifosfamide in Standard-Risk Patients and Assessment of Benefit of Etoposide Added to Standard Treatment in High-Risk Patients

(2008) Michael Paulussen et al.   JOURNAL OF CLINICAL ONCOLOGY

Allogeneic stem cell transplantation in a patient with relapsed Ewing sarcoma

(2008) Kenneth G. Lucas et al.   PEDIATRIC BLOOD & CANCER